← Back to Search

Anti-tumor antibiotic

Nivolumab for Non-Small Cell Lung Cancer

Phase 3
Waitlist Available
Led By David Gerber, MD
Research Sponsored by RTOG Foundation, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from registration to study termination. maximum follow-up was 14.9 months.
Awards & highlights

Study Summary

This trial tests if nivolumab can help treat Stage III lung cancer when used with radiation & chemotherapy.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from registration to study termination. maximum follow-up was 14.9 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from registration to study termination. maximum follow-up was 14.9 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Survival (OS)
Progression-Free Survival (PFS)
Secondary outcome measures
Number of Participants With Grade 3+ Adverse Events
Overall Survival by PD-L1 Status
Percentage of Participants With Deterioration in Functional Assessment of Cancer Therapy - Trial Outcome Index for Lung Cancer (FACT-TOI) at 15 Months
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NivolumabExperimental Treatment4 Interventions
60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
Group II: PlaceboPlacebo Group4 Interventions
60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Radiation Therapy (RT)
2008
Completed Phase 2
~230
Cisplatin
FDA approved
Etoposide
FDA approved
Nivolumab
FDA approved

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbIndustry Sponsor
2,646 Previous Clinical Trials
4,131,138 Total Patients Enrolled
RTOG Foundation, Inc.Lead Sponsor
6 Previous Clinical Trials
1,492 Total Patients Enrolled
David Gerber, MDPrincipal InvestigatorRTOG Foundation
5 Previous Clinical Trials
187 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
2016. "Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02768558.
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top